Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Investigational cytokine-targeted therapies for ulcerative colitis.

Monteleone G, Pallone F, Caprioli F.

Expert Opin Investig Drugs. 2013 Sep;22(9):1123-32. doi: 10.1517/13543784.2013.813931. Epub 2013 Jun 27. Review.

PMID:
23802627
2.

Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.

Lawrance IC.

Expert Opin Investig Drugs. 2015 Jun;24(6):761-8. doi: 10.1517/13543784.2015.1020371. Epub 2015 Feb 26. Review.

PMID:
25719407
3.

Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.

Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, Couturier D, Chaussade S.

Am J Gastroenterol. 1998 Dec;93(12):2397-404.

PMID:
9860399
4.

Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.

Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD.

Inflamm Bowel Dis. 2006 Oct;12(10):979-94.

PMID:
17012969
5.

Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Chande N, McDonald JW, Macdonald JK.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006774. doi: 10.1002/14651858.CD006774.pub2. Review. Update in: Cochrane Database Syst Rev. 2010;(10):CD006774.

PMID:
18425969
6.

Immunosuppressive and biologic therapy for ulcerative colitis.

Ardizzone S, Cassinotti A, de Franchis R.

Expert Opin Emerg Drugs. 2012 Dec;17(4):449-67. doi: 10.1517/14728214.2012.744820. Epub 2012 Nov 19. Review.

PMID:
23163556
7.

Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide.

Engel MA, Kellermann CA, Rau T, Burnat G, Hahn EG, Konturek PC.

J Physiol Pharmacol. 2008 Dec;59(4):673-89.

8.

Animal models of ulcerative colitis and their application in drug research.

Low D, Nguyen DD, Mizoguchi E.

Drug Des Devel Ther. 2013 Nov 12;7:1341-57. doi: 10.2147/DDDT.S40107. eCollection 2013. Review.

9.

Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Chande N, McDonald JW, Macdonald JK, Wang JJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006774. doi: 10.1002/14651858.CD006774.pub3. Review.

PMID:
20927749
10.

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.

Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R.

Scand J Gastroenterol. 2012 May;47(5):538-47. doi: 10.3109/00365521.2012.667146.

PMID:
22486187
11.

Emerging immunological targets in inflammatory bowel disease.

Monteleone G, Pallone F, MacDonald TT.

Curr Opin Pharmacol. 2011 Dec;11(6):640-5. doi: 10.1016/j.coph.2011.09.013. Epub 2011 Oct 12. Review.

PMID:
22000933
12.

Cyclosporine A for induction of remission in severe ulcerative colitis.

Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004277. Review.

PMID:
15674937
13.

Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.

Richter JM, Kushkuley S, Barrett JA, Oster G.

Aliment Pharmacol Ther. 2012 Aug;36(3):248-56. doi: 10.1111/j.1365-2036.2012.05175.x. Epub 2012 Jun 12.

14.

Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.

Deng X, Tolstanova G, Khomenko T, Chen L, Tarnawski A, Szabo S, Sandor Z.

J Pharmacol Exp Ther. 2009 Dec;331(3):1071-8. doi: 10.1124/jpet.109.158022. Epub 2009 Sep 17.

15.

Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis.

Kankuri E, Hämäläinen M, Hukkanen M, Salmenperä P, Kivilaakso E, Vapaatalo H, Moilanen E.

Scand J Gastroenterol. 2003 Feb;38(2):186-92.

PMID:
12678336
16.
17.

Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells.

Matsumura K, Nakase H, Kosugi I, Honzawa Y, Yoshino T, Matsuura M, Kawasaki H, Arai Y, Iwashita T, Nagasawa T, Chiba T.

Inflamm Bowel Dis. 2013 Aug;19(9):1951-63. doi: 10.1097/MIB.0b013e318293c5bf.

PMID:
23839229
18.

Emerging drugs for the treatment of ulcerative colitis.

Pastorelli L, Pizarro TT, Cominelli F, Vecchi M.

Expert Opin Emerg Drugs. 2009 Sep;14(3):505-21. doi: 10.1517/14728210903146882. Review.

19.

Emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. doi: 10.1517/14728210802591378 . Review. Erratum in: Expert Opin Emerg Drugs. 2009 Mar;14(1):205.

PMID:
19046132
20.

Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Saini SD, Waljee AK, Higgins PD.

Clin Gastroenterol Hepatol. 2012 Oct;10(10):1143-51. doi: 10.1016/j.cgh.2012.05.003. Epub 2012 May 18.

Items per page

Supplemental Content

Write to the Help Desk